{"PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "OtherAbstract": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "PMID": "16430090", "DateCompleted": {"Year": "2006", "Month": "03", "Day": "02"}, "DateRevised": {"Year": "2018", "Month": "12", "Day": "11"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": [], "Journal": {"ISSN": "0019-5189", "JournalIssue": {"Volume": "44", "Issue": "1", "PubDate": {"Year": "2006", "Month": "Jan"}}, "Title": "Indian journal of experimental biology", "ISOAbbreviation": "Indian J Exp Biol"}, "ArticleTitle": "Effect of BR-16A (Mentat), a polyherbal formulation on drug-induced catalepsy in mice.", "Pagination": {"StartPage": "45", "EndPage": "48", "MedlinePgn": "45-8"}, "Abstract": {"AbstractText": ["Parkinson's disease (PD) is a neurodegenerative disease characterized by the selective loss of dopamine (DA) neurons of the substantia nigra pars compacta (SNc). The events, which trigger and/or mediate the loss of nigral DA neurons, however, remain unclear. Neuroleptic-induced catalepsy has long been used as an animal model for screening drugs for Parkinsonism. Administration of haloperidol (1 mg/kg, ip) or reserpine (2 mg/kg, ip) significantly induced catalepsy in mice. BR-16A (50 and 100 mg/kg, po), a polyherbal formulation or ashwagandha (50 and 100 mg/kg, po), significantly reversed the haloperidol or reserpine-induced catalepsy. The results indicate that BR-16A or ashwagandha has protective effect against haloperidol or reserpine-induced catalepsy and provide hope that BR-16A could be used in preventing the drug-induced extrapyramidal side effects and may offer a new therapeutic approach to the treatment of Parkinson's disease."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "University Institute of Pharmaceutical Science, Panjab University, Chandigarh 160 014, India."}], "Identifier": [], "LastName": "Kumar", "ForeName": "Anil", "Initials": "A"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Kulkarni", "ForeName": "S K", "Initials": "SK"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "India", "MedlineTA": "Indian J Exp Biol", "NlmUniqueID": "0233411", "ISSNLinking": "0019-5189"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Mentat"}, {"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}, {"RegistryNumber": "8B1QWR724A", "NameOfSubstance": "Reserpine"}, {"RegistryNumber": "J6292F8L3D", "NameOfSubstance": "Haloperidol"}, {"RegistryNumber": "V038D626IF", "NameOfSubstance": "Ashwagandha"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["chemically induced", "drug therapy"], "DescriptorName": "Catalepsy"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": ["toxicity"], "DescriptorName": "Haloperidol"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Medicine, Ayurvedic"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": ["chemically induced", "drug therapy"], "DescriptorName": "Parkinsonian Disorders"}, {"QualifierName": [], "DescriptorName": "Phytotherapy"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Plant Extracts"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["toxicity"], "DescriptorName": "Reserpine"}, {"QualifierName": [], "DescriptorName": "Withania"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2006", "Month": "1", "Day": "25", "Hour": "9", "Minute": "0"}, {"Year": "2006", "Month": "3", "Day": "3", "Hour": "9", "Minute": "0"}, {"Year": "2006", "Month": "1", "Day": "25", "Hour": "9", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["16430090"]}}], "PubmedBookArticle": []}